Last reviewed · How we verify
NCT04272658: IMMUNOPET2
PET/CT Whole-body Dynamic Acquisition at FDG to Metastatic Melanoma Under Immunotherapy
trial testing value of 4D body-to-whole dynamic acquisition in FDG in Metastatic Melanoma in 56 participants. Currently enrolling.
26 June 2026
Quick facts
| Lead sponsor | University Hospital, Brest |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 56 |
| Start date | 26 June 2020 |
| Primary completion | 26 June 2026 |
| Estimated completion | 26 June 2026 |
| Sites | 1 location across France |
Drugs / interventions tested
- value of 4D body-to-whole dynamic acquisition in FDG
Conditions studied
- Metastatic Melanoma — all drugs for Metastatic Melanoma →
Sponsor
University Hospital, Brest
Who can join
18 and older, any sex, with Metastatic Melanoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The value of 4D body-to-whole dynamic acquisition in FDG PET / CT to differentiate progression / pseudo-progression during the first therapeutic assessment (PET1) of metastatic melanoma treated with immune checkpoint inhibitors (ICI)to predict the progression of the disease..
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Precision Nuclear Medicine: The Evolving Role of PET in Melanoma.
Wright CL, Miller ED, Contreras C, Knopp MV. · · 2021 · cited 5× · PMID 34392917 · DOI 10.1016/j.rcl.2021.05.007 -
Imaging the Rewired Metabolism in Lung Cancer in Relation to Immune Therapy.
van Genugten EAJ, Weijers JAM, Heskamp S, Kneilling M, et al · · 2021 · cited 2× · PMID 35070990 · DOI 10.3389/fonc.2021.786089
Verify or expand the search:
- PubMed search for NCT04272658
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Metastatic Melanoma
Currently open trials in the same condition.
- NCT06066138 — A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing · Phase 1 · recruiting
- NCT07237100 — Mirdametinib in Patients With Advanced NF1-mutant Melanoma · Phase 2 · recruiting
- NCT07086105 — A Study to Evaluate Adze1.C in Participants With Metastatic Melanoma · Phase 1 · recruiting
- NCT07112170 — Consolidative Use of Radiotherapy to Block Oligoprogression in Patients With Metastatic Melanoma · NA · recruiting
- NCT06488365 — In Vivo Liquid Biopsy of Melanoma (Cytophone) · NA · recruiting
Other University Hospital, Brest trials
Trials by the same sponsor.
- NCT07526688 — Aerobic Physical Activity and Orofacial Myofascial Pain · NA · not yet recruiting
- NCT07487155 — Unified Junction of Care, Integrated Treatments and Team Coordination for ADHD in Prison Settings With Substance Use Dis · NA · not yet recruiting
- NCT07417605 — Diagnostic Performance Of 4D Dynamic LAFOV FDG-PET Acquisition for Differentiation of Residual Disease and Post-radiatio · not yet recruiting
- NCT07302074 — Understanding of Rare Inflammatory Arthritis in Comparison to Classical Inflammatory Arthritis : Tissular Observations a · NA · recruiting
- NCT06441773 — Impact of Respiratory Rehabilitation on Quality of Life in Patients With Metastatic Non-small Cell Lung Cancer Treated W · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04272658 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University Hospital, Brest
- Last refreshed: 26 June 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04272658.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing